King Wins Preliminary Injunction In Skelaxin Battle
A federal judge has blocked CorePharma LLC from selling a generic version of King Pharmaceuticals Inc.'s patented muscle relaxant Skelaxin, and King has posted a $12 million preliminary injunction bond pending...To view the full article, register now.
Already a subscriber? Click here to view full article